TAFI deficiency in liver cirrhosis: Relation with plasma fibrinolysis and survival

Thrombosis Research

Volumn 121, Issue 6, 2008, Pages 763-768

  Gresele, Paolo ^a   Binetti, Bianca M ^b   Branca, Giovanna ^a   Clerici, Carlo ^a   Asciutti, Stefania ^a   Morelli, Antonio ^a   Semeraro, Nicola ^b   Colucci, Mario ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Child Pugh class; Fibrinolysis; Inflammation; Survival

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN DEFICIENCY; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR DEFICIENCY;

CARBOXYPEPTIDASE U; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 41749086931     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.08.011     Document Type: Article

References (21)

1. Joist J.H., and George J.N. Hemostatic abnormalities in liver and renal diseases. In: Colman R.W., Hirsh J., Marder V.J., Clowes A.W., and George J.N. (Eds). Hemostasis and thrombosis. Basic principles and clinical practice (2001), Lippincott Williams & Wilkins, Philadelphia 955-973
2. Lisman T., Leebeek F.W., and de Groot P.G. Haemostatic abnormalities in patients with liver disease. J Hepatol 37 (2002) 280-287
3. Agnholt J., Mikkelsen J.H., i Bud M., Moller-Petersen J., Rasmussen S.N., and Dyerberg J. Plasma prekallikrein as a prognostic indicator in chronic liver insufficiency. Scand J Gastroenterol 25 (1990) 40-44
4. Violi F., Ferro D., Basili S., Cimminiello C., Saliola M., Vezza E., et al. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. CALC Group. Hepatology 22 (1995) 96-100
5. Tacke F., Fiedler K., von Depka M., Luedde T., Hecker H., Manns M.P., et al. Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int 26 (2006) 173-181
6. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 33 (2003-2004) 375-381
7. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 20 (2000) 2511-2518
8. Myles T., Nishimura T., Yun T.H., Nagashima M., Morser J., Patterson A.J., et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 278 (2003) 51059-51067
9. Campbell W.D., Lazoura E., Okada N., and Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 46 (2002) 131-134
10. Van Thiel D.H., George M., and Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 85 (2001) 667-670
11. Lisman T., Leebeek F.W., Mosnier L.O., Bouma B.N., Meijers J.C., Janssen H.L., et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121 (2001) 131-139
12. Colucci M., Binetti B.M., Branca M.G., Clerici C., Morelli A., Semeraro N., et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 38 (2003) 230-237
13. Guarner C., and Runyon B.A. Spontaneous bacterial peritonitis: pathogenesis, diagnosis and management. Gastroenterology 3 (1995) 311-328
14. Körner T., Kropf J., Kosche B., Kristahl H., Jaspersen D., and Gressner A.M. Improvement of prognostic power of the Child-Pugh classification of liver cirrhosis by hyaluronan. J Hepatol 39 (2003) 947-953
15. Pugh R.N.H., Murray-Lyon I.M., Dawson J.L., Petroni M.C., and William R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646-649
16. Paquet K.J. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices - a prospective controlled randomized trial. Endoscopy 14 (1982) 4-5
17. Colucci M., Binetti B.M., Tripodi A., Chantarangkul V., and Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 103 (2004) 2157-2161
18. Zweig M.H., and Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39 (1993) 561-577
19. Swaisgood C.M., Schmitt D., Eaton D., and Plow E.F. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 110 (2002) 1275-1282
20. Asai S., Sato T., Tada T., Miyamoto T., Kimbara N., Motoyama N., et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol 173 (2004) 4669-4674
21. Campbell W., Yonezu K., Shinohara T., and Okada H. An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis. J Lab Clin Med 115 (1990) 610-612